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ABSTRACT 
Kyotorphin (KTP) is an endogenous peptide with analgesic properties when 
administered into the central nervous system (CNS). Its amidated form (L-Tyr-L-Arg-
NH2; KTP-NH2) has improved analgesic efficacy after systemic administration, 
suggesting blood-brain barrier (BBB) crossing. KTP-NH2 also has anti-inflammatory 
action impacting on microcirculation. In this work, selected derivatives of KTP-NH2 
were synthesized to improve lipophilicity and resistance to enzymatic degradation while 
introducing only minor changes in the chemical structure: N-terminal methylation 
and/or use of D amino acid residues.  
Intravital microscopy data show that KTP-NH2 having a D-Tyr residue, KTP-NH2-DL, 
efficiently decreases the number of leukocyte rolling in a murine model of inflammation 
induced by bacterial lipopolysaccharide (LPS): down to 46% after 30 min with 96 M 
KTP-NH2-DL. The same molecule has lower ability to permeate membranes (relative 
permeability of 0.38) and no significant activity in a behavioral test which evaluates 
thermal nociception (hot-plate test). On the contrary, methylated isomers at 96 M 
increase leukocyte rolling up to nearly 5-fold after 30 min suggesting a pro-
inflammatory activity. They have maximal ability to permeate membranes (relative 
permeability of 0.8) and induce long-lasting antinociception.  
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1. INTRODUCTION  
Kyotorphin is a small endogenous dipeptide, L-Tyr-L-Arg (KTP), firstly isolated from a 
bovine brain in 19791-2 and afterwards localized in the brain synaptosomes of 
mammals3. KTP is a powerful neuropeptide being four-fold more potent than 
endogenous opioids;1 however, the remarkable antinociceptive action of KTP in animal 
models was observed only when the molecule was administered directly into the CNS.4 
The reduced ability of KTP to cross the blood-brain barrier (BBB) is the most accepted 
explanation.5 The analgesia induced by KTP appears to be opioid-mediated via the 
release of the opioid Met-enkephalin involved in pain control.1, 6-7 It is suggested that 
KTP also mediates non-opioid activity without the release of enkephalins.8-9  
Recently we have found that amidated KTP (KTP-NH2) causes analgesia after systemic 
administration, which suggests KTP-NH2 is able to cross the BBB
10, in spite of modest 
permeation through lipid membranes.11 In addition, KTP levels in cerebro-spinal fluid 
correlate negatively with the progression of neurodegeneration in Alzheimer’s Disease 
patients12 and KTP-NH2 has neuroprotective effects in an animal model of dementia
13. 
Because recent evidence shows that Alzheimer’s Disease is primarily a vascular disease 
with neurodegenerative consequences, rather than a neurodegenerative disorder with 
vascular consequences,14 and the activity of KTP-NH2 at BBB level, we have raised the 
hypothesis that the endothelium is a key element in the pharmacological action of KTP-
NH2. In addition to its hypothetical endothelial targeting, KTP-NH2 is also an appealing 
drug lead because it does not cause damage on microcirculation,15 has no significant 
cytotoxic effects10 and does not induce the side effects associated to opioid drugs.16 
When covalently associated to ibuprofen, KTP-NH2 enhances the anti-inflammatory 
action of ibuprofen15 and the ibuprofen moiety enhances the analgesic action of KTP-
NH2.
17 Chemical manipulation of KTP-NH2 is a strategy to modulate its action. The key 
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elements of KTP-NH2 chemical nature that interfere with its biological action are the 
cationic charge18, lipophilicity19 and resistance to enzymatic degradation.10, 17 In this 
study we have pursued the goal of finding simple and inexpensive KTP-NH2 derivatives 
having endothelium-mediated action both as analgesic and anti-inflammatory drugs. 
The strategy was to explore enantiomers of KTP-NH2 by using D-Tyr and/or D-Arg 
residues and/or methylation capping at the N-terminus. All the derivatives are thus 
analogs of KTP-NH2 with minimal differences in structure, while exploring variation in 
charge, lipophilicity and resistance to peptidases. An integrated approach using in vivo 
data from intravital microscopy (IVM) and evaluation of thermal nociceptive responses 
in rodents, combined with mechanistic permeation data in vitro, was used to unravel 
new drug leads targeted to endothelium-mediated action with impact both in 
inflammation and analgesia. 
2. RESULTS 
2.1. Synthesis of kyotorphin derivatives 
First, amidated kyotorphin derivatives H-D-Tyr-Arg-NH2 (KTP-NH2-DL), H-Tyr-D-
Arg-NH2 (KTP-NH2-LD), H-D-Tyr-D-Arg-NH2 (KTP-NH2-DD), H-N-Me-Tyr-D-Arg 
(Me-KTP-NH2-LD) and H-N-Me-Tyr-Arg (Me-KTP-NH2) have been prepared in small 
scale through standard solid phase peptide synthesis using a 9-
fluorenylmethoxycarbonyl (Fmoc) / tert-butyl (t-Bu) strategy as illustrated in Scheme 1. 
Key elements of this solid-phase peptide synthesis are, employment of t-Bu group and 
2,2,5,7,8-pentamethyl-chroman-6-sulfonyl (pmc) group as masks for the side chains of 
tyrosine and arginine, respectively; removal of Fmoc groups by treatment with 30% 
piperidine in dimethylformamide (DMF) and amide couplings mediated by O-
(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) in the 
6 
 
presence of N-hydroxybenzotriazole (HOBt) as racemization suppressant and 
diisopropylethylamine (DIEA) as base. 
Fmoc-Rink-MBHA
1) Piperidine / DMF (3:7), rt
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Scheme 1. General synthetic route for solid phase synthesis of kyotorphin derivatives. 
The side chain protection of arginine is an unsolved problem in solid phase peptide 
synthesis because the usually employed arylsulfonyl-based protecting groups (e.g. 
pmc)20 are too stable to TFA and need extended cleavage to complete removal during 
the release step of the peptide from the support.21 In addition, sometimes they are also 
difficult to scavenge and have a tendency to reattach or alkylate sensitive residues. 
Knowing this, the release step of KTP-NH2-DL peptide was first examined using three 
different cleavage cocktails (Table 1). Reagents R22 and B23 are the most recommended 
cleavage cocktails for those peptides containing, among others amino acids residues, 
Arg(pmc). Nevertheless, under these conditions KTP-NH2-DL was obtained in poor 
purity together with a significant amount of peptide with arginine residue still pmc-
protected KTP-NH2-DL(pmc) and several no identified impurities (Table 1, entries 1 
and 2). The standard mixture of cleavage with TFA, water and triisopropylsilane (TIS) 
was tested at different cleavage times (Table 1, entries 3-6). After 2:20 hours treatment, 
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acceptable results of 80% purity of KTP-NH2-DL and only a 2% of KTP-NH2-DL(pmc) 
were obtained (Table 1, entry 5). Increasing cleavage time provided worse results 
(Table 1, entry 6). The best cleavage conditions were applied to the others kyotorphin 
derivatives which were obtained in a range of purities of 72-87%.  
Next, the crude kyotorphin derivatives were purified manually by reverse-phase flash 
chromatography and the pure peptides obtained were dissolved in 1M aqueous HCl and 
lyophilized for three times to afford kyotorphin derivatives as a hydrochloride salts, 
with final yields and purities shown in Table 2.  
Table 1. KTP-NH2-DL peptide submitted to different cleavage conditions 
Entry Cleavage cocktail 
Time 
(h) 
KTP-NH2-DL 
(%)c 
KTP-NH2-DL(pmc) 
(%)c 
1 
TFA / thioanisole / EDT / anisole
a
 
(90:5:3:2) 
2:00  55 3 
2 
TFA / phenol / H2O / TIS
b
 
(88:5:5:2) 
3:00  35 50 
3 
TFA / TIS / H2O 
(95:2.5:2.5) 
2:00  50 11 
4 
TFA / TIS / H2O 
(95:2.5:2.5) 
2:15 67 13 
5 
TFA / TIS / H2O 
(95:2.5:2.5) 
2:25 80 2 
6 
TFA / TIS / H2O 
(95:2.5:2.5) 
4:00  42 25 
aReagent R. bReagent B. cPercentage determined by HPLC at 220 nm from the crude peptide. 
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Table 2. Yields and purities of kyototphin derivatives synthesized in solid phase 
Reference Sequence Yield (%)a Purity (%)b 
HPLC  
tR (min) 
KTP-NH2-DL H-D-Tyr-Arg-NH2 52 99.9 2.35 
KTP-NH2-LD H-Tyr-D-Arg-NH2 70 98.2 2.41 
KTP-NH2-DD H-D-Tyr-D-Arg-NH2 80 99.9 1.52 
Me-KTP-NH2-LD H-N-Me-Tyr-D-Arg-NH2 60 97.7 2.28 
Me-KTP-NH2 H-N-Me-Tyr-Arg-NH2 58 98.7 1.66 
aYields were calculated from isolated product after reverse-phase flash chromatography. bPercentage 
determined by HPLC at 220 nm from the crude peptide. 
 
Lead kyotorphin derivatives KTP-NH2-DL, Me-KTP-NH2-LD and Me-KTP-NH2 have 
been prepared in large scale through standard solution phase peptide synthesis as 
illustrated in Scheme 2. Boc-Tyrosine building block are commercial available 
protected with benzyl (Bzl) group in the side chain. Amide coupling between tyrosine 
and arginine building blocks was mediated by benzotriazole-1-yl-oxy-tris-
(dimethylamino)-phosphonium hexafluorophosphate (BOP) in the presence of N-
methylmorpholine (NMM) at room temperature. Under these conditions all protected 
kyotorphin derivatives were obtained in moderate to good yields and in excellent 
purities (Scheme 2).  
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Scheme 2. Solution phase synthesis of kyotorphin derivatives 
In the case of methylated derivatives although a single peak by HPLC analysis was 
observed, its 1H NMR spectra showed some protons split specially for the α-carbonylic 
protons. In order to distinguish between a conformational equilibrium and a possible 
epimerization occurred during coupling reaction, a variable-temperature 1H NMR study 
was undertaken. At 20 ºC the α-carboxylic protons of Me-KTP-NH2-LD (protected) 
exhibit two separate and broad singlet signals, which coalesce between 40-60 ºC (Figure 
1), and sharpen even more at higher temperatures. These results are unequivocal 
evidence that the methylated kyotorphin derivatives present a slow conformational 
equilibrium which can be observed on the NMR time scale, and that epimerization 
process does not take place during coupling reaction. 
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Figure 1. 1H NMR spectra (region 4-8.5 ppm) of Me-KTP-NH2-DL (protected) 
recorded in DMSO-d6 from 20 to 110 ºC 
Next, Bzl and Boc protecting groups of the kyotorphin derivatives, were removed by 
catalytic hydrogenation and treatment with a 4M solution of HCl in dioxane 
respectively. Thus, the final kyotorphin derivatives were obtained as hydrochloride salt 
in good yields (Scheme 2). 
 
2.2. Selection of lead compounds based on lipid interaction and serum stability  
KTP-NH2 is unstable in human serum (90% conversion in free amino acids after 60 min 
by HPLC), KTP-NH2-LD is relatively stable (20% conversion), and the other 
derivatives are very stable (less than 10% conversion). Lipid interaction studies21  using 
anionic lipids to better mimic brain endothelium surface15 has shown a stronger 
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interaction of the derivatives KTP-NH2-DL, Me-KTP-NH2-LD, and Me-KTP-NH2 with 
lipid membranes (Figure 2), indicative of an increased potential to translocate 
membranes as insertion on lipid bilayers is the first key event in diffusion across 
membranes or receptor targeting. 21 Compounds KTP-NH2-DL, Me-KTP-NH2-LD, and 
Me-KTP-NH2 are the most promising both in terms of pharmacokinetics (stability in 
serum) and efficacy (potential to translocate the blood-brain barrier) and were therefore 
selected as lead compounds in this study. 
 
 
Figure 2: Normalized Tyr residue fluorescence emission upon titration of the KTP 
derivatives with lipid vesicles of POPG [1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-
glycero-3-phospho-(1'-rac-glycerol)], as described in references 21 and 14. Maximal 
deviation from the initial value of fluorescence intensity reflects how strongly the 
fluorescence quantum yield of Tyr residue is affected by contact with the lipid. KTP-
NH2-LD – Light blue; KTP-NH2-DL - pink, KTP-NH2-DD – green, Me-KTP-NH2-LD 
– Dark blue, and Me-KTP-NH2 – Orange. 
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2.3. Intravital microscopy studies 
Changes in the dynamics of microcirculation were evaluated by intravital microscopy 
following topical application of 20 L of KTP derivatives 48 or 96 M to mice 
cremaster muscle. Despite structural similarities, KTP derivatives presented distinct 
alterations in microcirculation. The peptide Me-KTP-NH2 increased hugely the number 
of rolling leukocytes in a concentration-dependent manner. Except that at 10 min, 48 
M of this peptide increased more leukocyte rolling than 96 M (p < 0.001). These 
values remained high, statistically unchanged, at 20 and 30 min (Figure 3A). The 
increase of rolling leukocytes caused by 48 M of Me-KTP-NH2 was about 4 fold 
compared to basal values (p < 0.001). At the highest concentration tested of 96 M, Me-
KTP-NH2 increased approximately 6 fold the leukocyte rolling compared to control and 
reached a plateau at 20 min (Figure 3A). Moreover, a transient arteriolar contraction 
was observed 10 min after topical application of 96 M Me-KTP-NH2 (Figure 3C), 
while lower concentration caused an arteriolar contraction in only 25% of tested 
animals. No adherent leukocytes were observed over the experiment (data not shown). 
The peptide Me-KTP-NH2-LD did not show a concentration-dependent behavior, but 
also increased leukocyte rolling, by approximately 3 fold (Figure 3A). Furthermore, 
Me-KTP-NH2-LD isomer did not induce arteriolar contraction nor increased the number 
of adherent leukocytes (data not shown). However, both Me-KTP-NH2-LD and Me-
KTP-NH2 showed pro-inflammatory properties.  
In contrast, KTP-NH2-DL did not increase leukocyte rolling (Figure 3A). Consequently, 
we decided to study its effects on LPS-induced inflammation model. Mice injected ip 
with 0.05 g/kg LPS present an average of 75 rolling leukocytes per min along the 
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vessel wall. Topical treatment with KTP-NH2-DL reduced that number to 
approximately 39 rolling leukocytes per min. This result evidence a potential role of this 
isomer as an anti-inflammatory compound. 
 
Figure 3. Effects of KTP-NH2 derivatives on microcirculation. (A) Number of rolling 
leukocytes per minute after topical application of 48 or 96 M of the KTP-NH2-DL, 
Me-KTP-NH2 and Me-KTP-NH2-LD peptides on the mice cremaster muscle (n ≥ 4) at 
different time points. Bars represent mean ± SEM. Basal values correspond to number 
of rolling leukocytes per minute before peptide application. The horizontal line 
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represents the average number of rolling leukocytes over time after PBS application. 
*** p < 0.001 compared to PBS using two way ANOVA followed by Tukey’s post test, 
### p < 0.001. (B) Number of rolling leukocytes per minute after challenge with LPS 
(0.05 g/kg, ip) and following topical treatment with 96 M of KTP-NH2-DL. 
Determinations were performed each 10 min up to 30 min after peptide topical 
application on the mice cremaster muscle (n = 4). Each point represents mean ± SEM. 
***p<0.001 compared with LPS (control group: topical application of PBS) using two-
way ANOVA followed by Tukey’s post test; (C) Transient arteriolar contraction at 10 
min after Me-KTP-NH2 (96 M) topical application. 
2.4. Evaluation of thermal nociceptive responses  
The analgesic effects of Me-KTP-NH2-LD and Me-KTP-NH2 were evaluated after ip 
administration to male Wistar rats. Both peptides induced a dose- and time-independent 
increased response threshold (average variation of 2-2.6ºC in relation to the respective 
baseline levels). In fact, after injection of Me-KTP-NH2-LD  at either 50 µmol/kg or  96 
µmol/kg  increases in threshold were detected  at all timepoints, except at 75 minutes 
(p<0.05 at 30 and 90 minutes and  p<0.01 at 15, 45 and 60 minutes for the dose 50 
µmol/kg; p<0.05 at 90 minutes, p<0.01 at 30 and 60 minutes and p<0.001 at 15 and 45 
minutes for the dose 96 µmol/kg; Figure 4). Regarding the injection of Me-KTP-NH2 at 
50 µmol/kg an increase in threshold was detected 15 (p<0.01) and 45 minutes post-
injection (p<0.05). With the 96µmol/kg the increases were detected at all the 
timepoints, except at 75 minutes (p<0.05 at 30, 60 and 90 minutes and p<0.01 at 15 and 
45 minutes; Figure 4). After injection with saline, the variations in relation to the 
respective baseline levels along the time were negligible or nil (Figure 4). Regarding the 
effects of the peptide KTP-NH2-DL, statistically significant increases were only 
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detected at 45 minutes with the dose of 50 µmol/kg (Figure 4). Overall, the results 
indicate an analgesic effect of both LL and LD Me-KTP-NH2 isomers, whereas the 
peptide KTP-NH2-DL did not show a relevant analgesic effect.  
 
 
 
Figure 4. Effect of KTP-NH2 derivatives on the nociceptive threshold of rats in the hot-
plate test. Results shown as the difference between responses at each time point relative 
to basal values (time zero, i.e. immediately before injection). Compounds were ip 
administered at 50 mol/kg (left panel) or 96 mol/kg (right panel). Each point 
represents mean ± SEM (n≥5). *** p < 0.001, ** p <0.01 and * p < 0.05 versus saline-
treated animals using two way ANOVA followed by Tukey’s post test. 
2.5. Permeation studies with drug candidates 
The time-dependence of the normalized fluorescence emission intensity of the drugs in 
covered and blank filters versus time is presented in Supporting information (Figure 
S1). The relative permeability was calculated for each drug candidate (Figure 5). The 
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PR of the five peptides ranged from 0.38 to 0.81, the highest value being attained by 
Me-KTP-NH2. The PR of KTP-NH2-DL was significantly inferior to the one of KTP. 
 
Figure 5. Relative permeability of Me-KTP-NH2, Me-KTP-NH2-LD, KTP-NH2-DL, 
KTP, and KTP-NH2. Data showed as mean ± SEM; each group is an average of three 
independent measures. *P < 0.05 versus KTP; "'P < 0.001 versus KTP-NH2. One-way 
ANOVA, followed by Tukey’s post test. 
3. DISCUSSION  
A new series of KTP-NH2 derivatives have been designed in order to improve 
endothelial targeting both at peripheral and BBB level and were evaluated for their 
impact on microcirculation and analgesic efficacy in vivo. The potential to transpose 
lipid membranes in vitro was also evaluated. Modifications consisted in N-terminal 
methylation and/or L to D amino acid change. 
The evaluation of the microcirculatory environment was assessed through IVM. This 
technique have been used for decades to help scientists understand the biophysical 
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conditions under which leukocytes are exposed to in microvessels 24-26. IVM provides a 
tool to acquire quantitative, qualitative, and dynamic insights into cell biology and 
endothelial-leukocyte interactions relevant to understanding the pathophysiology of 
inflammation in different disease states 27. 
After KTP derivatives application, the microcirculatory environment did not reveal 
toxic effects such as thrombi formation or contraction of myofibrils, however Me-KTP-
NH2 and Me-KTP-NH2-LD increased 6 and 3 fold, respectively, the number of rolling 
leukocytes relative to control (Figure 3), revealing a potential pro-inflammatory effect. 
However, vasodilatation, one of the earliest events of acute inflammation, was not 
detected. On the contrary, KTP-NH2-DL did not increase leukocyte rolling nor induced 
cellular recruitment. In addition, it decreased leukocyte rolling induced by LPS (Figure 
3B). This endotoxin is found in the outer membrane of Gram-negative bacteria and once 
LPS reaches the blood flow, it activates the CD14/toll-like receptor 4 (TLR4)/myeloid 
differentiation protein 2 (MD2) complex on the surface of immune cells consequently 
promoting the secretion of pro-inflammatory cytokines, nitric oxide, eicosanoids and 
inducing neutrophils recruitment. 
KTP-NH2-DL has low permeation across lipid membranes as PR = 0.4 (Figure 5), a 
value at which no significant analgesic effect is expected among KTP derivatives that 
diffuse across lipid bilayers.19 Consistently, KTP-NH2-DL has the lowest analgesic 
effect among the three lead drugs tested (Figure 4). KTP-NH2 is more effective than 
expected from simple inference based on PR19 but KTP-NH2-DL does not retain this 
property. As previously suggested19, KTP-NH2 probably uses an active transporter like 
peptide transporter 2 (PEPT2) to translocate the BBB. Data in Figure 3 corroborates this 
hypothesis as KTP-NH2-DL is an diastereoisomer of KTP-NH2 and completely loses 
efficacy. The data suggest that KTP-NH2 derivatives having high PR permeate through 
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the BBB passively and cause analgesia while KTP-NH2 uses a selective transporter. 
This hypothesis also explains why KTP-NH2 has a fast transient effect while methylated 
(Figure 5) and other derivatives have prolonged effects:10, 17 derivatization in both 
endings such as amidation at C terminus and methylation at N terminus, protects the 
peptides from the action of peptidases and proteases, improving pharmacokinetics. 
Me-KTP-NH2 is highly permeable having PR = 0.8. The addition of a neutral, 
hydrophobic methyl group to KTP-NH2 was a significant step to improve the interaction 
with lipid and confer increased membrane permeation. We have previously described a 
direct correlation between membrane permeation and analgesic activity.19 The data 
obtained in the hot-plate test corroborate this hypothesis. The analogs with higher PR, 
Me-KTP-NH2 and Me-KTP-NH2-LD, are the most effective in analgesia (Figure 4).  
In this study we have discovered KTP-NH2-DL, an anti-inflammatory drug lead, and 
Me-KTP-NH2, a very effective membrane-translocator analgesic drug lead. The parent 
molecule KTP-NH2 combines anti-inflammatory properties with analgesic efficacy. 
Isomerization of the Tyr residue (D-Tyr) decreases permeation through membranes and 
abrogates analgesic action. Methylation at the N terminus increases permeation and 
improves analgesic efficacy but abrogates anti-inflammatory action, probably a 
consequence of cell-penetration at the endothelium and/or blood cells. Since the hot-
plate is a behavioral test that evaluates  acute responses to thermal nociceptive 
stimulation and in which the inflammatory reaction is nil32, future studies will evaluate 
the effects of those analogs in inflammatory pain models, such as articular 
inflammation. 
The mechanism of action of KTP-NH2 is still not totally clarified but the dual effect of 
KTP-NH2
15 in pain and inflammation might shed light on this matter. Ueda and co-
workers suggested that KTP receptor is coupled to Gi protein and mediates calcium 
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influx via phospholipase C (PLC).28 PLC also plays an important role in the 
inflammation pathway catalyzing the release of arachidonic acid that subsequently 
promotes the release of prostaglandins and leukotrienes. It is reasonable to speculate 
that KTP-NH2 might interact with G protein coupled receptors that play a role 
simultaneously in pain and inflammation. A good hypothetic target would be the 
protease-activated receptors (PARs). They are widely distributed in a variety of tissues 
and can be activated by small peptides, triggering different intracellular pathway 
depending on the cell type. “PARs are in essence peptides receptors that carry their own 
ligand, which remain silent until unmasked by site-specific receptor cleavage”.29 Four 
PAR isoforms have been identified so far. PAR1 and PAR4 agonists are able to induce 
analgesia and inflammation, while PAR2 antagonist cause analgesia and are anti-
inflammatory. The interaction of KTP-NH2 with PARs could be the key to explain how 
KTP-NH2 and its derivatives impact on inflammation and analgesia.  
4. CONCLUSIONS 
1) KTP-NH2 is anti-inflammatory in mice as revealed by IVM and analgesic in rats as 
revealed by the hot plate test. Methylation at the N terminus enhances analgesic efficacy 
through increased permeation across lipid membranes but abrogates anti-inflammatory 
action. Isomerization of the L-Tyr residue has the opposite effect. 
2) Globally, the results support the hypothesis that KTP-NH2 uses a specific transporter 
across the BBB, not fitted to transport KTP-NH2 derivatives. Methylated derivatives 
permeate membranes passively and may diffuse across the BBB, thus compensating for 
the lack of activity of the transporter. 
3) KTP-NH2-DL has a pronounced anti-inflammatory action but low permeation 
through lipid membranes and decreased analgesic action. 
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In addition, the study opens new perspectives by casting the hypothesis that the 
interference of KTP-NH2 and its derivatives with PAR may be the key to understand the 
dual action of these drugs in inflammation and nociception. PARs are expressed in 
endothelial cells and neurons, besides platelets and myocytes. 
5. EXPERIMENTAL SECTION 
5.1. Peptide synthesis 
General Synthetic Procedures. KTP and KTP-NH2 were synthesized as described 
before.10 All chemicals used for peptide synthesis were purchased from Sigma-Aldrich, 
Fluka, Bachem or Iris-Biotech and used without further purification. The peptides 
synthesized in solid-phase were analyzed for purity on high performance liquid 
chromatography (HPLC) and characterized by mass spectra under electrospray 
ionization (ESI-MS) and proton nuclear magnetic resonance (1H-NMR). The peptides 
synthesized in solution phase were analyzed for purity on HPLC and characterized by 
1H-NMR, carbon nuclear magnetic resonance (13C NMR) and high resolution mass 
spectra under electrospray ionization (HRMS-ESI). HPLC analyses were carried out 
using a Dionex instrument composed of an UV/Vis Dionex UVD170U detector, a P680 
Dionex bomb, an ASI-100 Dionex automatic injector, and CHROMELEONTM 6.60 
software. Separations were achieved on an analytical 100-C18 Kromasil reversed phase 
column (4.6 mm x 40 mm; 3.5 m particle size). The compounds were eluted using a 
linear gradient of 0–100% CH3CN in 0.1% TFA at flow rate of 1.0 mL/min. The 
absorbance was measured at 220 nm. The HPLC retention time of each compound was 
determined when the peak was at its maximum height. NMR spectra were recorded at 
400 MHz on a Brucker DPX Advance spectrometer. Spectra recorded in DMSO-d6 
were referenced to residual DMSO-d6 at 2.50 ppm for 
1H or 39.5 ppm for 13C. Spectra 
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recorded in D2O were referenced to 4,4-dimethyl-4-silapentane-1-sulfonic acid (DDS = 
0.0 ppm) as an internal standard. Coupling constants (J) are given in Hertz (Hz). The 
following abbreviations were used for spin multiplicity: s = singlet, d = doblet, t = 
triplet, q = quarter, m = multiplet, dd = double doublet, bs = broad singlet. ESI-MS 
analyses were performed with an Esquire 6000 ESI ion Trap LC/MS (Bruker Daltonics) 
instrument equipped with an electrospray ion source. The instrument was operated in 
the positive ESI(+) ion mode. Samples (5 μL) were introduced into the mass 
spectrometer ion source directly through an HPLC autosampler. The mobile phase 
(80:20 CH3CN/H2O at a flow rate of 100 μLmin–1) was delivered by a 1100 Series 
HPLC pump (Agilent). Nitrogen was employed as both the drying and nebulising gas. 
HRMS were recorded under conditions of ESI with a Bruker MicroTof-Q instrument 
using a hybrid quadrupole time-of-flight mass spectrometer (University of Zaragoza). 
Samples were introduced into the mass spectrometer ion source directly through a 1100 
Series Agilent HPLC autosampler and were externally calibrated using sodium formate. 
The instrument was operated in the positive ESI(+) ion mode. Reverse-phase flash 
chromatography (RF-FC) purifications were performed manually on C18-reverse-phase 
silica gel 100 (400 mesh, Fluka). 
 
5.1.1. Solid phase synthesis of peptides KTP-NH2-DL, KTP-NH2-LD, KTP-NH2-DD, 
Me-KTP-NH2-LD and Me-KTP-NH2.  
General procedure. Peptides were prepared manually by the solid-phase method using 
Fmoc-type chemistry, Fmoc-Rink-MBHA resin (0.56 mmol/g) as solid support, tert-
butyl side chain protection for tyrosine and pmc for arginine. Coupling of amino acids 
was mediated by a mixture of HBTU (3.8 equiv), HOBt (4 equiv), and DIEA (3 equiv) 
in DMF at room temperature for 1 hour. The completion of the reactions was monitored 
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by the Kaiser test. Fmoc group was removed by treating the resin with 30% piperidine 
in DMF (2 + 8 min). After each coupling and deprotection step, the resin was washed 
with DMF (6 x 1 min) and air-dried. A mixture of TFA, water and TIS was used as 
cleavage cocktail. 
The Fmoc-Rink-MBHA resin (450 mg) was placed into a plastic syringe fitted with a 
polypropylene frit to remove the Fmoc group and subsequently couple with arginine 
amino acid (4 equiv). After Fmoc group removal the resin was treated with tyrosine 
derivative (4 equiv). The resulting dipeptides were deprotected with piperidine and 
released from the solid support by treatment with TFA/H2O/TIS (95:2.5:2.5) with 
stirring for 2.25 h at room temperature. Following TFA evaporation and diethyl ether 
extraction, the crude peptides were purified by reverse-phase flash chromatography 
(H2O/MeOH/TFA 90:10:0.01%). The resulting white solid was dissolved in 1M 
aqueous HCl and lyophilized. This process was repeated three times to afford 
kyotorphin derivatives as a hydrochloride salt. 
 
KTP-NH2-DL. By the general procedure, Fmoc-Arg(pmc)-OH (4 equiv) and Fmoc-D-
Tyr(tBu)-OH (4 equiv) provided H-D-Tyr-Arg-NH2 (48 mg, 52%) as a colorless solid. 
HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 min): retention time, 2.36 min; 
99.9% pure. 1H NMR (D2O, 400 MHz): δ 1.02-1.22 (m, 2H, CH2CH2NHarginine), 1.42-
1.52 (m, 1H of the CH2CHarginine), 1.59-1.69 (m, 1H of the CH2CHarginine), 2.99 (dd, J = 
13.4 Hz, J’ = 10.3 Hz, 1H of the CH2-tyrosine), 3.02-3.05 (m, 2H, CH2-arginine), 3.22 (dd, 
J = 13.4 Hz, J’ = 5.8 Hz, 1H of the CH2-tyrosine), 4.08 (dd, J = 9.6 Hz, J’ = 4.5 Hz, 1H, 
CH-arginine), 4.18 (dd, J = 10.3 Hz, J’ = 5.8 Hz, 1H, CH-tyrosine), 6.88 (d, J = 8.5 Hz, 
2H, CHaryl), 7.15 (d, J = 8.5 Hz, 2H, CHaryl). MS (ESI) m/z = 337.1 [M+H]
+, 169.0 
[M+2H]2+.  
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KTP-NH2-LD. By the general procedure, Fmoc-D-Arg(pmc)-OH (4 equiv) and Fmoc-
Tyr(tBu)-OH (4 equiv) provided H-Tyr-D-Arg-NH2 (66 mg, 70%) as a colorless solid. 
HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 min): retention time, 2.41 min; 99% 
pure. 1H NMR (D2O, 400 MHz): δ 1.00-1.19 (m, 2H, CH2CH2NHarginine), 1.42-1.52 (m, 
1H of the CH2CHarginine), 1.59-1.68 (m, 1H of the CH2CHarginine), 2.96 (dd, J = 13.3 Hz, 
J’ = 10.3 Hz, 1H of the CH2-tyrosine), 3.01-3.04 (m, 2H, CH2-arginine), 3.21 (dd, J = 13.3 
Hz, J’ = 5.8 Hz, 1H of the CH2-tyrosine), 4.06 (dd, J = 9.6 Hz, J’ = 4.5 Hz, 1H, CH-
arginine), 4.17 (dd, J = 10.3 Hz, J’ = 5.8 Hz, 1H, CH-tyrosine), 6.87 (d, J = 8.5 Hz, 2H, 
CHaryl), 7.14 (d, J = 8.5 Hz, 2H, CHaryl). MS (ESI) m/z = 337.1 [M+H]
+, 169.0 
[M+2H]2+.  
 
KTP-NH2-DD. By the general procedure, Fmoc-D-Arg(pmc)-OH (4 equiv) and Fmoc-
D-Tyr(tBu)-OH (4 equiv) provided H-D-Tyr-D-Arg-NH2 (75 mg, 80%) as a colorless 
solid. HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 min): retention time, 1.52 min; 
99.9% pure. 1H NMR (D2O, 400 MHz): δ 1.49-1.62 (m, 2H, CH2CH2NHarginine), 1.65-
1.86 (m, 2H, CH2CHarginine), 3.10-3.17 (m, 4H, CH2-arginine and CH2-tyrosine), 4.20-4.26 
(m, 2H, CH-tyrosine and CH-arginine), 6.85 (d, J = 8.4 Hz, 2H, CHaryl), 7.13 (d, J = 8.4 
Hz, 2H, CHaryl). MS (ESI) m/z = 337.1 [M+H]
+, 169.0 [M+2H]2+.  
 
Me-KTP-NH2-LD. By the general procedure, Fmoc-D-Arg(pmc)-OH (4 equiv) and 
Fmoc-N-Me-Tyr(tBu)-OH (4 equiv) provided N-Me-Tyr-D-Arg-NH2 (58 mg, 60%) as a 
colorless solid. HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 min): retention time, 
2.29 min; 97.7% pure. 1H NMR (D2O, 400 MHz): δ 0.98-1.18 (m, 2H, 
CH2CH2NHarginine), 1.39-1.49 (m, 1H of the CH2CHarginine), 1.56-1.65 (m, 1H of the 
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CH2CHarginine), 2.73 (s, 3H, NCH3), 2.94 (dd, J = 13.1 Hz, J’ = 11.0 Hz, 1H of the CH2-
tyrosine), 2.99-3.04 (m, 2H, CH2-arginine), 3.30 (dd, J = 13.1 Hz, J’ = 5.3 Hz, 1H of the 
CH2-tyrosine), 4.04 (dd, J = 9.8 Hz, J’ = 4.6 Hz, 1H, CH-arginine), 4.07 (dd, J = 11.0 Hz, 
J’ = 5.3 Hz, 1H, CH-tyrosine), 6.87 (d, J = 8.5 Hz, 2H, CHaryl), 7.13 (d, J = 8.5 Hz, 2H, 
CHaryl). MS (ESI) m/z = 351.1 [M+H]
+, 176.0 [M+2H]2+.  
 
Me-KTP-NH2. By the general procedure, Fmoc-Arg(pmc)-OH (4 equiv) and Fmoc-N-
Me-Tyr(tBu)-OH (4 equiv) provided N-Me-Tyr-Arg-NH2 (56 mg, 58%) as a colorless 
solid. HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 min): retention time, 1.66 min; 
98.7% pure. 1H NMR (D2O, 400 MHz): δ 1.50-1.58 (m, 2H, CH2CH2NHarginine), 1.63-
1.70 (m, 1H of the CH2CHarginine), 1.72-1.80 (m, 1H of the CH2CHarginine), 2.71 (s, 3H, 
NCH3), 3.06 (dd, J = 13.8 Hz, J’ = 9.0 Hz, 1H of the CH2-tyrosine), 3.17 (t, 2H, J = 6.9 
Hz, CH2-arginine), 3.20 (dd, J = 13.8 Hz, J’ = 5.7 Hz, 1H of the CH2-tyrosine), 4.12 (dd, J 
= 9.0 Hz, J’ = 5.7 Hz, 1H, CH-tyrosine), 4.42 (dd, J = 7.8 Hz, J’ = 6.8 Hz, 1H, CH-
arginine), 6.86 (d, J = 8.5 Hz, 2H, CHaryl), 7.12 (d, J = 8.5 Hz, 2H, CHaryl). MS (ESI) m/z 
= 351.1 [M+H]+, 176.0 [M+2H]2+.  
 
5.1.2. Solution phase synthesis of peptides KTP-NH2-DL, Me-KTP-NH2-LD and Me-
KTP-NH2 
General procedure for the coupling reaction between tyrosine and arginine derivatives. 
NMM (3 equiv, 30 mmol) was added to a solution of tyrosine derivative (1 equiv, 10 
mmol) in DMF (40 mL), and the resulting mixture was stirred at room temperature for 1 
h. Then, BOP (1 equiv, 10 mmol) and arginine derivative (1.05 equiv, 10.5 mmol) were 
added. The resulting reaction mixture was stirred overnight at room temperature. Upon 
completion of the reaction (HPLC monitoring), the reaction mixture was filtered. The 
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resulting solution was diluted with ethyl acetate (100 mL), washed with saturated 
sodium bicarbonate (3 x 50 mL), water (100 mL), 1M aqueous potassium 
hydrogensulfate (3 x 50 mL), and brine (50 mL). The organic layer was dried over 
magnesium sulfate, filtered and concentrated under reduced pressure. The crude 
material was triturated with n-pentane, filtered, washed with n-pentane and dried to 
obtain the expected peptides which were used in the next step without further 
purification. 
 
Synthesis of Boc-D-Tyr(Bzl)-Arg-NH2. By the general procedure, Boc-D-Tyr(Bzl)-OH 
(3.71 g, 10 mmol) and H-D-Arg-NH2 2HCl (2.58 g, 10 mmol) provided Boc-D-
Tyr(Bzl)-Arg-NH2 (3.15 g, 60%) as a colorless solid. 
1H-NMR (DMSO-d6 + a drop 
D2O, 400 MHz): δ 1.19-1.28 (m, 2H of the CH2CH2NHarginine), 1.28 (s, 9H, (CCH3)3), 
1.37-1.43 (m, 1H of the CH2CHarginine), 1.68-1.70 (m, 1H of the CH2CHarginine), 2.68 (dd, 
J = 13.6 Hz, J’ = 9.2 Hz, 1H of the CH2-tyrosine), 2.82 (dd, J = 13.6 Hz, J’ = 5.2 Hz, 1H 
of the CH2-tyrosine), 2.99 (taparent, J = 6.8 Hz, 2H, CH2-arginine), 4.06-4.11 (m, 2H, CH-
tyrosine and CH-arginine), 5.01 (s, 2H, CH2O), 6.87 (d, J = 8.4 Hz, 2H, CHaryl), 7.00 (d, J 
= 7.2 Hz, 1H, NH), 7.12 (d, J = 8.4 Hz, 2H, CHaryl), 7.17 (br, 1H, NH), 7.29-7.40 (m, 
5H, CHaryl), 8.12 (d, J = 8.0 Hz, 1H, NH). 
13C NMR (DMSO-d6, 100 MHz): δ 24.8 (t), 
28.2 (q, 3C), 28.9 (t), 36.3 (t), 40.3 (t), 51.8 (d), 56.3 (d), 69.1 (t), 78.2 (s), 114.3 (d, 
2C), 127.6 (d, 2C), 127.7 (d), 128.4 (d, 2C), 130.0 (s), 130.2 (d, 2C), 137.2 (s), 155.6 
(s), 156.7 (s), 156.9 (s), 171.8 (s), 173.3 (s). HRMS (ESI) m/z calcd. for C27H39N6O5 
[M+H]+ 527.2976, found 527.3005. HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 
min): retention time, 7.45 min; 99.9% pure. 
 
26 
 
Synthesis of Boc-N-Me-Tyr(Bzl)-D-Arg-NH2. By the general procedure, Boc-N-Me-
Tyr(Bzl)-OH (3.85 g, 10 mmol) and H-D-Arg-NH2 2HCl (2.58 g, 10.5 mmol) provided 
Boc-N-Me-Tyr(Bzl)-D-Arg-NH2 (4.86 g, 90%) as a colorless solid. 
1H NMR (DMSO-
d6, 400 MHz, 110 ºC): δ 1.34 (s, 9H, (CCH3)3), 1.46-1.53 (m, 2H, CH2CH2NHarginine), 
1.55-1.63 (m, 1H of the CH2CHarginine), 1.72-1.81 (m, 1H of the CH2CHarginine), 2.69 (s, 
3H, NCH3), 2.83 (m, 1H of the CH2-tyrosine), 3.10-3.14 (m, 3H, CH2-arginine and 1H of 
the CH2-tyrosine), 4.25-4.30 (m, 1H, CH-arginine), 4.69 (dd, J = 10.0 Hz, J’ = 5.6 Hz, 1H, 
CH-tyrosine), 5.05 (s, 2H, CH2O), 6.83 (br, 4H, NH), 6.90 (d, J = 8.4 Hz, 2H, CHaryl), 
7.10 (d, J = 8.4 Hz, 2H, CHaryl), 7.28-7.40 (m, 5H, CHaryl). 
13C NMR (DMSO-d6, 100 
MHz, 80 ºC): δ 24.5 (t), 27.5 (q, 3C), 28.7 (t), 30.6 (q), 33.2 (t), 40.1 (t), 51.5 (d), 59.7 
(d), 69.2 (t), 78.7 (s), 114.4 (d, 2C), 126.9 (d, 2C), 127.1 (d), 127.8 (d, 2C), 129.4 (d, 
2C), 129.9 (s), 136.9 (s), 154.6 (s), 156.7 (s), 156.9 (s), 169.7 (s), 172.6 (s). HRMS 
(ESI) m/z calcd. for C28H41N6O5 [M+H]
+ 541.3133, found 541.3151. HPLC 
(water/acetonitrile, 0.1% TFA, 2-100%, 17 min): retention time, 7.68 min; 99.9% pure. 
 
Synthesis of Boc-N-Me-Tyr(Bzl)-Arg-NH2. By the general procedure, Boc-N-Me-
Tyr(Bzl)-OH (3.85 g, 10 mmol) and H-Arg-NH2 2HCl (2.58 g, 10.5 mmol) provided 
Boc-N-Me-Tyr(Bzl)-D-Arg-NH2 (4.91 g, 91%) as a colorless solid. 
1H NMR (DMSO-
d6, 400 MHz, 80ºC): δ 1.32 (s, 9H, (CCH3)3), 1.46-1.58 (m, 2H, CH2CH2NHarginine), 
1.60-1.64 (m, 1H of the CH2CHarginine), 1.75-1.83 (m, 1H of the CH2CHarginine), 2.70 (s, 
3H, NCH3), 2.85 (dd, J = 14.4 Hz, J’ = 10.4 Hz, 1H of the CH2-tyrosine), 3.11-3.17 (m, 
4H, CH2-arginine, 1H of the CH2-tyrosine and CH-tyrosine), 4.25-4.30 (m, 1H, CH-
arginine), 5.07 (s, 2H, CH2O), 6.91 (d, J = 8.6 Hz, 2H, CHaryl), 6.85 (br, 5H, NH), 7.14 
(d, J = 8.6 Hz, 2H, CHaryl), 7.30-7.43 (m, 3H, CHaryl), 7.49-7.51 (m, 2H, CHaryl). 
13C 
NMR (DMSO-d6, 100 MHz, 80 ºC): δ 24.6 (t), 27.6 (q, 3C), 28.9 (t), 30.5 (q), 33.0 (t), 
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40.1 (t), 51.7 (d), 59.5 (d), 69.2 (t), 78.7 (s), 114.4 (d, 2C), 126.9 (d, 2C), 127.2 (d), 
127.9 (d, 2C), 129.3 (d, 2C), 129.9 (s), 136.9 (s), 154.6 (s), 156.68 (s), 156.72 (s), 169.8 
(s), 172.6 (s). HRMS (ESI) m/z calcd. for C28H41N6O5 [M+H]
+ 541.3133, found 
541.3150. HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 min): retention time, 7.62 
min; 99.9% pure. 
 
General procedure for the removal of OBzl and N-Boc groups. The corresponding 
protected peptides (1 equiv) were dissolved in 50 mL of EtOH in a 100 mL two-neck 
round bottom flask. Pd/C (10 mol%) was added to the solution and the mixture was 
degassed twice under vacuum (using a water pump) and was replacing each time the 
vacuum by hydrogen (H2 balloon). Next, the reaction mixture was permitted to react at 
room temperature under a hydrogen flow (H2 balloon). After completion of the reaction 
(HPLC monitoring), the mixture was filtered through a Celite® bed to remove Pd/C, and 
the filtrate was evaporated in vacuo. The crude product was then dissolved in 50 mL of 
HCl 4M in 1,4-dioxane and stirred at room temperature. After completion of the 
reaction (HPLC monitoring), the resulting precipitate was collected by filtration, 
washed with 1,4-dioxane (2 x 10 mL), diethyl ether (2 x 10 mL) and n-pentane (2 x 10 
mL) and dried in vacuo. The resulting white solid was dissolved in water and 
lyophylized to afford the corresponding deprotected dipeptides. 
 
Synthesis of KTP-NH2-DL. By the general procedure, Boc-D-Tyr(Bzl)-Arg-NH2 (2.89 
g, 5.5 mmol) provided H-D-Tyr-Arg-NH2 (1.31 g, 71%) as a colorless solid. 
1H-NMR 
(D2O, 400 MHz): as describe above. 
13C NMR (D2O, 100 MHz): δ 27.2 (t), 30.9 (t), 
39.0 (t), 43.3 (t), 56.2 (d), 57.5 (d), 118.7 (d, 2C), 128.6 (s), 133.6 (d, 2C), 158.1 (s), 
159.6 (s), 172.3 (s), 178.8 (s). HRMS (ESI) m/z calcd. for C15H25N6O3 [M+H]
+ 
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337.1983, found 337.1988. HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 min): 
retention time, 2.36 min; 99.9% pure. 
 
Synthesis of Me-KTP-NH2-LD. By the general procedure, Boc-N-Me-Tyr(Bzl)-D-
Arg-NH2 (4.32 g, 8.0 mmol) provided N-Me-Tyr-D-Arg-NH2 (1.71 g, 61%) as a 
colorless solid. 1H-NMR (D2O, 400 MHz): as describe above. 
13C NMR (D2O, 100 
MHz): δ 27.2 (t), 30.8 (t), 34.4 (q), 38.0 (t), 43.3 (t), 56.4 (d), 65.7 (d), 118.7 (d, 2C), 
128.2 (s), 133.6 (d, 2C), 158.1 (s), 159.6 (s), 171.1 (s), 178.6 (s). HRMS (ESI) m/z 
calcd. for C16H26N6NaO3 [M+Na]
+ 373.1959, found 373.1961; calcd. for C16H27N6O3 
[M+H]+ 351.2139, found 351.2154. HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 
min): retention time, 2.29 min; 99.0% pure. 
 
Synthesis of Me-KTP-NH2. By the general procedure, Boc-N-Me-Tyr(Bzl)-Arg-NH2 
(4.32 g, 8.0 mmol) provided N-Me-Tyr-Arg-NH2 (2.24 g, 81%) as a colorless solid. 
1H-
NMR (D2O, 400 MHz): as describe above. 
13C NMR (D2O, 100 MHz): δ 27.2 (t), 31.1 
(t), 34.6 (q), 38.2 (t), 43.4 (t), 56.1 (d), 65.6 (d), 118.8 (d, 2C), 127.8 (s), 133.7 (d, 2C), 
158.1 (s), 159.6 (s), 170.6 (s), 177.5 (s). HRMS (ESI) m/z calcd. for C16H27N6O3 
[M+H]+ 351.2139, found 351.2139. HPLC (water/acetonitrile, 0.1% TFA, 2-100%, 17 
min): retention time, 1.66 min; 99.0% pure. 
 
5.2. Animals 
For the sake of the 3R´s policy on animal experimentation, a preliminary screening test 
was performed to reduce the number of compounds to be tested. Given the number of 
tests and replicates, each drug lead to be withdrawn from the study impacts significantly 
on the number of animals to be manipulated and sacrificed. Three lead compounds were 
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selected from in vitro determination of the affinity of the compounds to anionic lipid 
membranes: Me-KTP-NH2, Me-KTP-NH2-LD, and KTP-NH2-DL; Me stands for 
methylation at the N terminus and D refers to the use of a D-Tyr residue (DL) or a D-
Arg residue (LD). Data on KTP-NH2 was published before
10, 15 and used for 
comparison. 
5.2.1. Mice 
Male Swiss mice (4-6 weeks old) were obtained from a colony at Butantan Institute, 
São Paulo, Brazil. Animals were maintained in sterile microisolator cages with sterile 
rodent feed and acidified water ad libitum, and housed in positive-pressure air-
conditioned units (25°C, 50% relative humidity) on a 12 h light/dark cycle. All 
procedures were performed in accordance with the guidelines provided by the Brazilian 
College of Animal Experimentation. 
5.2.2 Rats 
Adult male Wistar rats (Charles River, L’Arbresle, France), weighing between 210 and 
250 g, were housed in groups at temperature and light-controlled conditions (22±2 ºC; 
lights on between 7:00 a.m. and 7:00 p.m.), with free access to food and water. In order 
to induce habituation to the researcher and to minimize stress, the animals were gently 
handled daily in the test room and hot-plate device during 4 days prior to nociceptive 
evaluation. At the day of experiments, animals were brought to the same room for at 
least 2h before testing. All experiments were performed in accordance with the 
European Directive 2010/63/EU. The project was approved by the institutional Animal 
Welfare Body (ORBEA-IMM) and licensed by DGAV (Direcção Geral de Veterinária) 
– the Portuguese competent authority for animal welfare. 
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5.3. Intravital microscopy 
The dynamics of alterations in the microcirculatory network were determined using 
intravital microscopy (IVM), a light microscopy-based approach that enables imaging 
subcellular structures in live animals. Endothelial cells can actively regulate the 
migration of leukocytes through the vessel wall by expressing adhesion molecules and 
chemokines on their luminal surface, allowing leukocytes to adhere and finally migrate 
into the tissue. The cremaster muscle was used as the principal tissue for analysis of 
leukocyte–vessel wall interactions because of its thin and transparent nature. IVM was 
conducted on an upright microscope (Axiolab, Carl Zeiss, Oberkochen, Germany) 
coupled to a digital camera for image acquisition (AxioCam Icc1, Carl Zeiss, 
Oberkochen, Germany).  
5.3.1. Cremaster muscle preparation 
Mice were injected ip with a muscle relaxant drug (0.4% xylazine) (Calmiun®, Agner 
União, São Paulo, Brazil) and after 5 min anesthetized with 0.5 g/Kg of ketamine 
(Holliday-Scott SA, Buenos Aires, Argentina) ip. Animals were placed on a 37ºC 
heating pad and the microsurgery was performed as described previously.30 Briefly, the 
scrotum was opened and the cremaster muscle exteriorized. A longitudinal incision on 
the muscle allowed its exposure to full access to the microcirculatory network. Post-
capillary venules were measured with Axiovision program v 4.8.2.0, and one venule 
ranging between 25-40 m of diameter in each animal was chosen to count the number 
of rolling leukocytes. 
5.3.2. Leukocyte recruitment measurements31 
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After stabilization of the microcirculation, the number of rolling and adherent 
leukocytes in the postcapillary venules were counted every 10 min, up to 30 min, after 
peptide topical application. A leukocyte was considered to be adhering to the venular 
endothelium if it remained stationary for 60 s or longer at a pre-set distance of 100 μM. 
A rolling leukocyte was defined as a white cell that moved slower than the stream of 
flowing erythrocytes. The number of rolling leukocytes was quantified as the number of 
white cells that passed a fixed pre-set point during 1 min. 
5.3.3. Experimental Protocol for IVM 
Initially, cremaster muscles of mice were topically applied with 20 L of KTP-NH2-DL, 
Me-KTP-NH2, or Me-KTP-NH2-LD at 48 or 96 M for visualization of their capacity to 
induce mobilization of leukocytes along the vessel wall. Sterile phosphate-buffered 
saline (PBS, pH 7.4) was used as control. 
For investigation of the anti-inflammatory effect of KTP-NH2-DL, mice were pretreated 
with an ip injection of LPS at 0.05 g/kg (E. coli 055:B5, Sigma) dissolved in sterile 
saline. 30 min after ip administration of LPS, cremaster muscles of mice were exposed 
to a topic application of 20 L of KTP-NH2-DL at 96 M. Negative-control mice were 
pretreated with ip injection of sterile saline and submitted to topic application of sterile 
PBS. Positive-control mice were pretreated with ip injection of LPS and submitted to 
topic application of sterile PBS. 
5.4. Evaluation of thermal nociceptive responses in the hot-plate test32  
The hot plate test consisted in evaluation of animal behavioral responses to noxious 
thermal stimulus, such as hind-paw withdrawal and/or shaking.33 The hot plate test is 
frequently elected to evaluate behavioral responses to acute nociceptive stimulation and 
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has the advantage over other acute behavioral tests of depending on central processing 
and not being a simple spinal reflex.32 The hot plate test is frequently the only acute 
behavioral test used to predict the analgesic efficacy of new drugs.34-37 Based on these 
reasons and in order to allow comparisons of the results of the present study with our 
previous reports with KTP derivatives10, 17, the hot plate test was elected. Animals were 
placed inside a transparent glass box (20.5x10 cm; 20 cm height) on the metallic surface 
of the hot plate apparatus (IITC Incremental Hot/Cold plate, Series 8/Software, IITC 
Life San Fernando Valley, CA, USA). The initial temperature was 35.2°C, and an 
increasing rate temperature of 9°C per minute was defined (cut-off at 52,5ºC). The 
temperature to elicit a pain behavior was recorded. A cut-off temperature of 52.5°C was 
defined. Animals (n ≥ 5 per group) were evaluated before Me-KTP-NH2, Me-KTP-NH2-
LD, KTP-NH2-DL or saline injection (basal values) and 15, 30, 45, 60, 75 and 90 min 
after ip injections. The responses are shown as the difference between values at each 
time point after injection and the respective basal values (at time zero). This is a solid 
procedure which allows that the response of each animal is analyzed and compared with 
the respective baseline values along the time.10, 17, 38 Data are represented as the group 
means ± SEM. The significance of differences in each group was analyzed with two 
way ANOVA followed by Tukey’s post hoc test (section 5.6). 
 
5.5. Permeation studies 
Permeation studies were performed in a 24-well transwell permeable supports. They 
were carried out for 18 h and were performed in triplicate. The basal compartment was 
filled with 800 L of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, pH 
7.4) buffer and the apical compartment loaded with 200 L of the drug solution. The 
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apical compartment was placed on top of the base being separated by a filter with or 
without lipid (sample versus blank filter). The apparatus were then incubated at 25ºC in 
an orbital shaker at 100 rpm for different time intervals. After incubation, the apparatus 
was disassembled and the basal and apical solutions were kept at 4ºC until use. Samples 
were transferred to standard 10 mm path length quartz cuvettes and the fluorescence 
emission intensity was measured in a spectrofluorimeter (FS920, Edinburgh 
Instruments, Livingston, UK), at room temperature. The spectroscopic experiments 
were as described elsewhere.17 After permeation assays, the samples were diluted to an 
absorbance bellow 0.1 at the excitation wavelength to minimize inner filter effects.39 
The dose tested was based on a previous study showing that the analgesic dose of KTP-
NH2, 32.3 mg·kg
-1 = 96 M, was efficient in all pain models tested.10 Thus, stock 
solutions of KTP-NH2 isomers and KTP were prepared by dissolving in HEPES buffer 
to a final apical concentration of 1.6 mM. 
5.5.1. Relative permeability calculation 
The fluorescence intensity of the drug at the apical compartment was plotted against 
time and the slope, m, of the linear part of the curves (approximate steady-state flux 
rate) at t=0 was calculated for both samples (filter + lipid bilayers’ stack) and blank 
filters (i.e. in the absence of lipid). Sample permeability (Ps) and blank permeability 
(Pb) may be simply calculated according to:11 
A
V
mP xx 
        (2) 
where x refers to sample (s) or blank (b), V is the basal volume, and A the area of the 
filter. Experimentally the relative permeability (PR) reads: 
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       (3) 
PR was calculated considering the first 10 hours, during which it was observed an 
approximate linear regime for the majority of drugs (Supporting information).  
5.5.2. Preparation of lipid barriers 
The preparation of the lipid barrier was described elsewhere.19 Shortly, small 
unilamellar vesicles (SUVs) of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) were prepared. The deposited lipid film was hydrated with HEPES buffer to a 
final concentration of 5 mM. The lipid was then homogenized by 8 cycles of freeze-
thawing and dissolved with HEPES buffer to a final concentration of 1 mM. SUVs were 
obtained by sonication with a tip sonicator (Vibra cell – Sonics & Material Inc, Danbury 
Connecticut, USA) operated in a continuous mode for 15 min with refrigeration, 
followed by centrifugation (Eppendorf centrifuge) at maximum speed for 30 min to 
remove titanium particles. 
100 L of the vesicular suspension was deposited to each culture insert in the transwells 
(0.4 µm pore size, 0.33 cm2 area), and 10 mM of CaCl2 was added to promote the 
formation of fused vesicles. The inserts were placed into 24-wells culture plate, and 
centrifuged at 693 × g (2000 rpm) (Multifuge 1L-R, Heraeus, Germany) for 4 min, at 
room temperature. The inserts were then placed in fresh wells, and 100 L of the 
vesicular suspension were again added to the filters followed by centrifugation at the 
same speed for 10 min. To improve lipid dispersion in the filter area, the plates were 
rotated 180 ºC between centrifugations. The inserts were placed in a new plate and 
incubated at 50 ºC for 25 min. After 5 min at room temperature, 100 L of the 
liposomal suspension were added to the filters and centrifuged for 30 min. Few filters 
35 
 
did not hold the lipid suspension and were excluded from the experiment.40 The 
remaining filters were carefully inverted to discard the supernatant. Thereafter, the 
filters were froze/thawed at -80 ºC for 1 h and 65 ºC for 30 min, followed by incubation 
overnight at 4 ºC until permeation studies. 
 
5.6. Statistical analyses 
Data are represented as mean ± SEM. Statistically differences were analyzed by one-
way or two-way ANOVA followed by Tukey’s post test. Differences were considered 
significant when p < 0.05. p < 0.01 and p < 0.001 are also mentioned where applicable 
for the sake of completeness of the results. All statistical analyses were calculated with 
Prism 6 software (GraphPad Software, version 6.02). 
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